Cotazym and Humalog drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cotazym (pancrelipase (amylase;lipase;protease)) and Humalog (insulin lispro recombinant). Common drug interactions include blood pressure decreased among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Cotazym and Humalog. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Cotazym?

Cotazym has active ingredients of pancrelipase (amylase;lipase;protease). eHealthMe is studying from 377 Cotazym users. Check the latest studies of Cotazym.

What is Humalog?

Humalog has active ingredients of insulin lispro recombinant. It is often used in diabetes. eHealthMe is studying from 137,127 Humalog users. Check the latest studies of Humalog.

On Jul, 16, 2026

14 people who take Cotazym and Humalog together, and have interactions are studied.

What are the common drug interactions of Cotazym and Humalog, by gender? *:

female:

Blood pressure decreased
Bronchopulmonary aspergillosis allergic (allergic lung disorder caused by aspergillus fungi)
Cough
Dyspnoea (difficult or laboured respiration)
Dyspnoea exertional (breathlessness or shortness of breath)
Forced expiratory volume decreased (decreased lung expired air volume)
Lung disorder (lung disease)
Malaise (a feeling of general discomfort or uneasiness)
Obstructive airways disorder (a progressive disease that makes it hard to breathe)
Productive cough

male:

Death
Beta haemolytic streptococcal infection (infection with streptococcus pyogenes, a beta-haemolytic bacterium cause mild to moderately severe respiratory tract, skin, and soft tissue)
Cellulitis (infection under the skin)
Drug hypersensitivity

What are the common drug interactions of Cotazym and Humalog, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Asthenia (weakness)
Chest discomfort
Cystic fibrosis (disease of the secretary glands)
Dyspnoea (difficult or laboured respiration)
Forced expiratory volume decreased (decreased lung expired air volume)
Lung disorder (lung disease)
Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
Staphylococcal infection (an infection with staphylococcus bacteria)

30-39:

Heart rate increased
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Lower respiratory tract infection
Nasopharyngitis (inflammation of the nasopharynx)
Neuralgia (pain in one or more nerves)
Weight decreased
Blood pressure increased
Fatigue (feeling of tiredness)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Headache (pain in head)

40-49:

Beta haemolytic streptococcal infection (infection with streptococcus pyogenes, a beta-haemolytic bacterium cause mild to moderately severe respiratory tract, skin, and soft tissue)
Cellulitis (infection under the skin)
Death

50-59:

n/a

60+:

Death
Drug hypersensitivity
Drug ineffective

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 4 people, 28.57%
Asthma: 4 people, 28.57%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 2 people, 14.29%
Osteoporosis (bones weak and more likely to break): 2 people, 14.29%
Indigestion: 1 person, 7.14%
High Blood Pressure: 1 person, 7.14%
Carcinoid Syndrome (syndrome includes flushing and diarrhoea, and, less frequently, heart failure and bronchoconstriction): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Cotazym and Humalog?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously